CTLA4 and B-cell chronic lymphocytic leukemia: In contrast, this form of immunotherapy might benefit CLL patients with low CTLA-4 expression on leukaemic cells (which predicts a poor clinical outcome), since CTLA-4 blockade does not affect proliferation and apoptosis of malignant B cells in this group.